Lung Chemotherapy protocols and prescriptions
Blank Chemotherapy Prescriptions
Included are blank chemocare regimen specific prescription files to be used as a part of local Trust contingency plan if the Chemocare Network Systems are not available. Network Chemocare Blank Lung Prescription templates zip folders – Lung blank scripts 1 of 2 and Lung blank scripts 2 of 2 . Last updated 22.12.2017.
Chemotherapy Protocols
The documents below are Northern Cancer Alliance (NCA) approved protocols for the management of patients receiving chemotherapy for Lung Cancers. All prescribing, preparation, dispensing and administration of chemotherapy should be within a framework of safe practice.
DISCLAIMER: The protocols on this website are for local guidance only, their accuracy cannot be guaranteed, please refer the SPC for information on the individual products. There are a number of protocols that are past their expiry/ review date. These are retained on the website for information only following requests from local Trusts, they must only be used on the understanding the responsibility for the use lies with local organisation and not NCA. NCA cannot accept responsibility for the validity of content of any documents that are past the review date.
No | Regime Name | Valid Until | Protocol |
---|---|---|---|
L001 | Oral vinorelbine | March 2021 | Download |
L002 | NP (Cisplatin – vinorelbine) | March 2021 | Download |
L003 | CAV (or VAC) (Cyclophosphamide, vincristine & doxorubicin) | March 2021 | Download |
L004 | Carboplatin – vinorelbine | March 2021 | Download |
L008 | Carboplatin- Etoposide 3 weekly | March 2021 | Download |
L009 | Carboplatin & Gemcitabine | March 2021 | Download |
L010 | Docetaxel | March 2021 | Download |
L011 | Gemcitabine | A/W Update | |
L014 | Carboplatin & Paclitaxel | March 2021 | Download |
L015 | Oral Topotecan | March 2021 | Download |
L016 | Cisplatin – Pemetrexed | March 2021 | Download |
L017 | Carboplatin – Pemetrexed | March 2021 | Download |
L018 | Erlotinib | March 2021 | Download |
L020 | Nintedanib and Docetaxel | March 2021 | Download |
L022 | Gefitinib (Iressa) | March 2021 | Download |
L023 | Crizotinib in NSCLC | March 2021 | Download |
L024 | Afatinib in NSCLC | March 2021 | Download |
L025 | Ceritinib | March 2021 | Download |
L026 | Osimertinib | March 2021 | Download |
L027 | Pembrolizumab first-line | March 2021 | Download |
L028 | Nivolumab | September 2021 | Download |
L029 | Pemetrexed maintenance | March 2021 | Download |
L030 | Alectinib | September 2021 | Download |
S003 | Pembrolizumab second-line | March 2021 | Download |
U019 | Atezolizumab | September 2021 | Download |
Discontinued documents | |||
L005 | MVP (Mitomycin, vinblastine, cisplatin) | May 2016 | |
L006 | MVCarbo (Mitomycin, vinblastine, carboplatin) | May 2016 | |
L007 | CEQ4W (Carboplatin – Etoposide 4 weekly) | May 2016 | |
L012 | Docetaxel & Cisplatin | May 2016 | |
L013 | Turrisi Cisplatin, Etoposide | May 2016 |